vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Edison International (EIX). Click either name above to swap in a different company.
Edison International is the larger business by last-quarter revenue ($5.2B vs $2.8B, roughly 1.9× Bausch Health Companies Inc.). Edison International runs the higher net margin — 35.4% vs -3.7%, a 39.1% gap on every dollar of revenue. On growth, Edison International posted the faster year-over-year revenue change (30.8% vs 9.3%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $-319.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 13.1%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Edison International is a public utility holding company based in Rosemead, California. Its subsidiaries include Southern California Edison, and unregulated non-utility business assets Edison Energy. Edison's roots trace back to Holt & Knupps, a company founded in 1886 as a provider of street lights in Visalia, California.
BHC vs EIX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $5.2B |
| Net Profit | $-103.0M | $1.8B |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 52.8% |
| Net Margin | -3.7% | 35.4% |
| Revenue YoY | 9.3% | 30.8% |
| Net Profit YoY | -205.1% | 443.5% |
| EPS (diluted) | $-0.30 | $4.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $5.2B | ||
| Q3 25 | $2.7B | $5.8B | ||
| Q2 25 | $2.5B | $4.5B | ||
| Q1 25 | $2.3B | $3.8B | ||
| Q4 24 | $2.6B | $4.0B | ||
| Q3 24 | $2.5B | $5.2B | ||
| Q2 24 | $2.4B | $4.3B | ||
| Q1 24 | $2.2B | $4.1B |
| Q4 25 | $-103.0M | $1.8B | ||
| Q3 25 | $179.0M | $832.0M | ||
| Q2 25 | $148.0M | $343.0M | ||
| Q1 25 | $-58.0M | $1.4B | ||
| Q4 24 | $98.0M | $340.0M | ||
| Q3 24 | $-85.0M | $516.0M | ||
| Q2 24 | $10.0M | $439.0M | ||
| Q1 24 | $-64.0M | $-11.0M |
| Q4 25 | 17.0% | 52.8% | ||
| Q3 25 | 23.1% | 24.9% | ||
| Q2 25 | 17.5% | 17.1% | ||
| Q1 25 | 12.2% | 56.0% | ||
| Q4 24 | 21.8% | 19.8% | ||
| Q3 24 | 12.7% | 19.1% | ||
| Q2 24 | 16.2% | 20.8% | ||
| Q1 24 | 13.1% | 6.0% |
| Q4 25 | -3.7% | 35.4% | ||
| Q3 25 | 6.7% | 14.5% | ||
| Q2 25 | 5.8% | 7.6% | ||
| Q1 25 | -2.6% | 37.7% | ||
| Q4 24 | 3.8% | 8.5% | ||
| Q3 24 | -3.4% | 9.9% | ||
| Q2 24 | 0.4% | 10.1% | ||
| Q1 24 | -3.0% | -0.3% |
| Q4 25 | $-0.30 | $4.78 | ||
| Q3 25 | $0.48 | $2.16 | ||
| Q2 25 | $0.40 | $0.89 | ||
| Q1 25 | $-0.16 | $3.72 | ||
| Q4 24 | $0.24 | $0.89 | ||
| Q3 24 | $-0.23 | $1.32 | ||
| Q2 24 | $0.03 | $1.13 | ||
| Q1 24 | $-0.17 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $158.0M |
| Total DebtLower is stronger | $20.8B | $38.0B |
| Stockholders' EquityBook value | $-554.0M | $17.6B |
| Total Assets | $26.4B | $94.0B |
| Debt / EquityLower = less leverage | — | 2.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $158.0M | ||
| Q3 25 | $1.3B | $364.0M | ||
| Q2 25 | $1.7B | $140.0M | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $193.0M | ||
| Q3 24 | $719.0M | $200.0M | ||
| Q2 24 | $595.0M | $465.0M | ||
| Q1 24 | $733.0M | $992.0M |
| Q4 25 | $20.8B | $38.0B | ||
| Q3 25 | $21.0B | $36.4B | ||
| Q2 25 | $21.7B | $37.7B | ||
| Q1 25 | $21.5B | $38.4B | ||
| Q4 24 | $21.6B | $35.6B | ||
| Q3 24 | $21.5B | $34.9B | ||
| Q2 24 | $21.7B | $34.8B | ||
| Q1 24 | $22.1B | $34.7B |
| Q4 25 | $-554.0M | $17.6B | ||
| Q3 25 | $-565.0M | $17.2B | ||
| Q2 25 | $-764.0M | $16.7B | ||
| Q1 25 | $-1.2B | $16.6B | ||
| Q4 24 | $-1.3B | $15.6B | ||
| Q3 24 | $-1.2B | $15.7B | ||
| Q2 24 | $-1.2B | $15.4B | ||
| Q1 24 | $-1.1B | $15.2B |
| Q4 25 | $26.4B | $94.0B | ||
| Q3 25 | $26.8B | $90.5B | ||
| Q2 25 | $27.3B | $88.8B | ||
| Q1 25 | $26.4B | $88.4B | ||
| Q4 24 | $26.5B | $85.6B | ||
| Q3 24 | $26.5B | $84.7B | ||
| Q2 24 | $26.5B | $84.8B | ||
| Q1 24 | $26.9B | $83.6B |
| Q4 25 | — | 2.16× | ||
| Q3 25 | — | 2.12× | ||
| Q2 25 | — | 2.26× | ||
| Q1 25 | — | 2.31× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 2.23× | ||
| Q2 24 | — | 2.26× | ||
| Q1 24 | — | 2.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $1.6B |
| Free Cash FlowOCF − Capex | $403.0M | $-319.0M |
| FCF MarginFCF / Revenue | 14.4% | -6.1% |
| Capex IntensityCapex / Revenue | 3.3% | 36.3% |
| Cash ConversionOCF / Net Profit | — | 0.85× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $-715.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $1.6B | ||
| Q3 25 | $405.0M | $2.1B | ||
| Q2 25 | $289.0M | $882.0M | ||
| Q1 25 | $211.0M | $1.2B | ||
| Q4 24 | $601.0M | $1.2B | ||
| Q3 24 | $405.0M | $2.5B | ||
| Q2 24 | $380.0M | $329.0M | ||
| Q1 24 | $211.0M | $1.0B |
| Q4 25 | $403.0M | $-319.0M | ||
| Q3 25 | $314.0M | $618.0M | ||
| Q2 25 | $190.0M | $-830.0M | ||
| Q1 25 | $96.0M | $-184.0M | ||
| Q4 24 | $495.0M | $-326.0M | ||
| Q3 24 | $334.0M | $961.0M | ||
| Q2 24 | $302.0M | $-1.1B | ||
| Q1 24 | $129.0M | $-236.0M |
| Q4 25 | 14.4% | -6.1% | ||
| Q3 25 | 11.7% | 10.7% | ||
| Q2 25 | 7.5% | -18.3% | ||
| Q1 25 | 4.2% | -4.8% | ||
| Q4 24 | 19.3% | -8.2% | ||
| Q3 24 | 13.3% | 18.5% | ||
| Q2 24 | 12.6% | -25.2% | ||
| Q1 24 | 6.0% | -5.8% |
| Q4 25 | 3.3% | 36.3% | ||
| Q3 25 | 3.4% | 26.2% | ||
| Q2 25 | 3.9% | 37.7% | ||
| Q1 25 | 5.1% | 36.9% | ||
| Q4 24 | 4.1% | 37.6% | ||
| Q3 24 | 2.8% | 29.1% | ||
| Q2 24 | 3.2% | 32.8% | ||
| Q1 24 | 3.8% | 31.4% |
| Q4 25 | — | 0.85× | ||
| Q3 25 | 2.26× | 2.55× | ||
| Q2 25 | 1.95× | 2.57× | ||
| Q1 25 | — | 0.85× | ||
| Q4 24 | 6.13× | 3.44× | ||
| Q3 24 | — | 4.79× | ||
| Q2 24 | 38.00× | 0.75× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
EIX
| Commercial | $2.2B | 43% |
| Residential | $1.2B | 23% |
| Other | $966.0M | 19% |
| Other Operating Revenue | $802.0M | 15% |
